Literature DB >> 30319976

Association Between Genetic Variant in the Promoter of Pri-miR-34b/c and Risk of Glioma.

Jinghui Li1,2, Xiaoyu Liu1, Yu Qiao2, Renli Qi2, Shunjin Liu1, Jing Guo1, Yang Gui2, Juanjuan Li1, Hualin Yu2.   

Abstract

Growing evidence indicates that p53 can regulate the expression of miRNAs, particularly the miR-34 family members, which are described as potential tumor suppressors. Loss of miR-34 suppresses TP53-mediated cell death, whereas over expression of miR-34 induced apoptosis. The study designed to investigate the association between the pir-miR-34b/c rs4938723, TP53 Arg72Pro and the risk of glioma. We genotyped the two polymorphisms in175 glioma patients and 235 healthy controls using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and DNA sequencing assay. Association analysis showed that the CC genotype of the pir-miR-34b/c rs4938723 was associated with a significantly decreased risk of glioma compared to the TT genotype (CC vs. TT: adjusted OR = 0.43;95% CI, 0.21-0.87,P = 0.02). Moreover, a significant association between the patients with glioma and controls was also observed in a recessive model (OR = 0.41; 95% CI, 0.21-0.81, P = 0.007). In contrast, the CC genotype of the TP53 Arg72Pro was associated with a significantly increased risk of glioma compared to the GG genotype (CC vs. GG: adjusted OR = 1.73;95% CI, 1.04-2.89,P = 0.04), and a significant association between the patients with glioma and controls was also observed in a recessive model (OR = 2.00; 95% CI, 1.26-3.18, P = 0.003). These findings suggest that the pri-miR-34b/c rs4938723CC and TP53 Arg72-Pro polymorphisms may be associated with the risk of glioma.

Entities:  

Keywords:  TP53; genetic variant; glioma; miR-34b/c; polymorphism

Year:  2018        PMID: 30319976      PMCID: PMC6170877          DOI: 10.3389/fonc.2018.00413

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  38 in total

1.  Efficacy of intratumoral chemotherapy using arsenic trioxide (As2O3) sustained release tablets for the treatment of neurogliocytoma in nude mice.

Authors:  H-B Zhao; Q-X Sun; X-F Chen; D-Y Han; S-G Zhao
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014       Impact factor: 3.507

2.  Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma.

Authors:  Lijuan Li; Jian Wu; Xiutian Sima; Peng Bai; Wei Deng; Xueke Deng; Lin Zhang; Linbo Gao
Journal:  Tumour Biol       Date:  2013-03-17

3.  Parental Perceptions of Obesity and Obesity Risk Associated With Childhood Acute Lymphoblastic Leukemia.

Authors:  Gary L Jones; Wendy McClellan; Sripriya Raman; Ashley Sherman; Erin Guest; Keith August
Journal:  J Pediatr Hematol Oncol       Date:  2017-07       Impact factor: 1.289

4.  Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil.

Authors:  Dayane B Koshiyama; Patrícia Trevisan; Carla Graziadio; Rafael F M Rosa; Bibiana Cunegatto; Juliete Scholl; Valentina O Provenzi; Alexandre P de Sá; Fabiano P Soares; Maíra C Velho; Nelson de A P Filho; Ceres A Oliveira; Paulo R G Zen
Journal:  J Neurooncol       Date:  2017-08-30       Impact factor: 4.130

Review 5.  Epidemiology of brain tumors.

Authors:  Hiroko Ohgaki
Journal:  Methods Mol Biol       Date:  2009

Review 6.  Targeting mutant p53 for efficient cancer therapy.

Authors:  Vladimir J N Bykov; Sofi E Eriksson; Julie Bianchi; Klas G Wiman
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

Review 7.  Promising therapeutic targets in neuroblastoma.

Authors:  Katherine K Matthay; Rani E George; Alice L Yu
Journal:  Clin Cancer Res       Date:  2012-05-15       Impact factor: 12.531

Review 8.  Cognition and resective surgery for diffuse infiltrative glioma: an overview.

Authors:  Martin Klein; Hugues Duffau; Philip C De Witt Hamer
Journal:  J Neurooncol       Date:  2012-02-24       Impact factor: 4.130

9.  miR-34 miRNAs provide a barrier for somatic cell reprogramming.

Authors:  Yong Jin Choi; Chao-Po Lin; Jaclyn J Ho; Xingyue He; Nobuhiro Okada; Pengcheng Bu; Yingchao Zhong; Sang Yong Kim; Margaux J Bennett; Caifu Chen; Arzu Ozturk; Geoffrey G Hicks; Greg J Hannon; Lin He
Journal:  Nat Cell Biol       Date:  2011-10-23       Impact factor: 28.824

10.  The association between the TP53 Arg72Pro polymorphism and colorectal cancer: An updated meta-analysis based on 32 studies.

Authors:  Xin Tian; Shundong Dai; Jing Sun; Shenyi Jiang; Youhong Jiang
Journal:  Oncotarget       Date:  2017-01-03
View more
  4 in total

Review 1.  The comprehensive landscape of miR-34a in cancer research.

Authors:  Sijing Li; Xiaohui Wei; Jinyong He; Quanquan Cao; Danyu Du; Xiaoman Zhan; Yuqi Zeng; Shengtao Yuan; Li Sun
Journal:  Cancer Metastasis Rev       Date:  2021-05-06       Impact factor: 9.264

2.  Association between miRNA polymorphisms and susceptibility to brain tumors: A meta-analysis.

Authors:  Fu'an Gao; Yuntao Zhu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

3.  Platelet-Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma.

Authors:  Lingling Wu; Qin Li; Junjie Deng; Jinglan Shen; Weide Xu; Wei Yang; Bingyu Chen; Yaoqiang Du; Wei Zhang; Feihang Ge; Siyun Lei; Kaiqiang Li; Zhen Wang
Journal:  Int J Nanomedicine       Date:  2021-12-29

4.  Association of TP53 rs1042522 C>G Polymorphism with Glioma Risk in Chinese Children.

Authors:  Fan Liao; Li Yuan; Jinhong Zhu; Wei Chen; Yemu Zhao; Jing He
Journal:  Biomed Res Int       Date:  2022-08-13       Impact factor: 3.246

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.